Liquid medicine for autism in children and teens
Part of Mental health clinical trials.
This trial tests an oral liquid medicine (called NTI164) to see if it helps reduce symptoms of autism in children and teens. It may be an option if current treatments haven't fully helped, but it requires regular study visits and certain health rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 6 and 21 years old
- Have a formal diagnosis of autism (Level II or III support needs)
- Be able to swallow liquids
- Have stable autism-related treatments for at least 12 weeks before starting
- Not be taking certain medications or cannabis-based products
- Not have a history of severe mental health conditions like schizophrenia or active major depression
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether N-acetylcysteine, a medicine taken by mouth, can improve autism-related restricted and repetitive behaviors in children. It looks at children who are showing at least moderate severity in these behaviors and may involve brain testing for safety reasons.
This study tests an experimental medication called TB006 for adults with autism. It aims to see if it can help reduce symptoms. Participants must be 18–35, have moderate-to-severe autism, and have a caregiver who can join them.
This study observes how intranasal insulin (a form of insulin delivered through the nose) affects children and young adults with autism spectrum disorder who are already using or planning to use it as part of their regular care. Researchers will track changes in behavior and social skills over about 6 months.
This study looks at whether N-acetylcysteine (NAC), a supplement/medication, can help autism-related symptoms by trying to target brain chemistry. You may be able to join if you previously took part in a related NAC study and can keep your usual medications steady.
This trial tests whether low doses of a protein called interleukin-2 (IL-2) can help reduce the symptoms of autism in children aged 6 to 8. It is designed for children whose mothers had a specific immune system condition or a severe infection during pregnancy.
This Phase 2 study tests whether a single dose of N-acetylcysteine can improve “restricted and repetitive behaviors” in children with autism. It’s meant for kids who are stable and still in early puberty stages.
Hear when a new Autism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.